MedTrace Logo

Finasteride Treatment of Severe Nodulocystic Acne

NCT02502669 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2019-02-15

No results posted yet for this study

Summary

Double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of once weekly, high dose oral finasteride compared to placebo for the treatment of severe nodulocystic acne in male subjects.

Conditions

  • NODULOCYSTIC ACNE

Interventions

DRUG

Finasteride 23.5 mg tablets

DRUG

Finasteride 33.5 mg tablets

DRUG

Placebo tablets

Sponsors & Collaborators

  • Elorac, Inc.

    lead INDUSTRY

Principal Investigators

  • Scott B. Phillips, MD · Elorac, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-06-06
Completion
2017-06-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02502669 on ClinicalTrials.gov